Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center
Background: The introduction of trastuzumab biosimilars in clinical practice plays an important role in promoting the sustainability of healthcare systems. By contrast, the switching process can be challenging to the clinics. This survey describes the switching process at a National Cancer Institute...
| Main Authors: | , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2021-05-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/13/5/684 |
| _version_ | 1797534732596019200 |
|---|---|
| author | Michela Piezzo Roberta D’Aniello Ilaria Avallone Bruno Barba Daniela Cianniello Stefania Cocco Antonio D’Avino Germira Di Gioia Vincenzo Di Lauro Giuseppina Fusco Raffaele Piscitelli Claudia von Arx Michelino De Laurentiis Piera Maiolino |
| author_facet | Michela Piezzo Roberta D’Aniello Ilaria Avallone Bruno Barba Daniela Cianniello Stefania Cocco Antonio D’Avino Germira Di Gioia Vincenzo Di Lauro Giuseppina Fusco Raffaele Piscitelli Claudia von Arx Michelino De Laurentiis Piera Maiolino |
| author_sort | Michela Piezzo |
| collection | DOAJ |
| description | Background: The introduction of trastuzumab biosimilars in clinical practice plays an important role in promoting the sustainability of healthcare systems. By contrast, the switching process can be challenging to the clinics. This survey describes the switching process at a National Cancer Institute over a period of 2 years. Methods: Data regarding all trastuzumab-based regimens for breast cancer (BC) from 1 January 2019 and 31 December 2020 were extracted from both adverse drug reactions (ADRs) reporting systems and electronic systems involved in inventory management, prescribing, dispensing, and administration. Both patients under monotherapy and combination treatment regimens were included. There were no exclusion criteria. Results and Conclusions: Overall 354 patients received at least one trastuzumab-based regimen for a total of 493 lines of treatment and 5769 administrations. Biosimilar were used in 34.3% of trastuzumab-based treatments. No differences between biosimilars and reference drug have been observed in terms of ADRs. The effective cost-saving of the first 2 years is greater than EUR 800,000 and it is estimated to increase over time. |
| first_indexed | 2024-03-10T11:34:37Z |
| format | Article |
| id | doaj.art-606ff46d6a98435db203621155ad3571 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-10T11:34:37Z |
| publishDate | 2021-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-606ff46d6a98435db203621155ad35712023-11-21T18:58:52ZengMDPI AGPharmaceutics1999-49232021-05-0113568410.3390/pharmaceutics13050684Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer CenterMichela Piezzo0Roberta D’Aniello1Ilaria Avallone2Bruno Barba3Daniela Cianniello4Stefania Cocco5Antonio D’Avino6Germira Di Gioia7Vincenzo Di Lauro8Giuseppina Fusco9Raffaele Piscitelli10Claudia von Arx11Michelino De Laurentiis12Piera Maiolino13Department of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyPharmacy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyDepartment of Experimental Medicine, Azienda Ospedaliera Universitaria degli Studi della Campania “Luigi Vanvitelli”, 80138 Naples, ItalyPharmacy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyPharmacy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyPharmacy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyDepartment of Breast and Thoracic Oncology, Division of Breast Medical Oncology, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyPharmacy, Istituto Nazionale Tumori IRCCS “Fondazione G. Pascale”, 80131 Naples, ItalyBackground: The introduction of trastuzumab biosimilars in clinical practice plays an important role in promoting the sustainability of healthcare systems. By contrast, the switching process can be challenging to the clinics. This survey describes the switching process at a National Cancer Institute over a period of 2 years. Methods: Data regarding all trastuzumab-based regimens for breast cancer (BC) from 1 January 2019 and 31 December 2020 were extracted from both adverse drug reactions (ADRs) reporting systems and electronic systems involved in inventory management, prescribing, dispensing, and administration. Both patients under monotherapy and combination treatment regimens were included. There were no exclusion criteria. Results and Conclusions: Overall 354 patients received at least one trastuzumab-based regimen for a total of 493 lines of treatment and 5769 administrations. Biosimilar were used in 34.3% of trastuzumab-based treatments. No differences between biosimilars and reference drug have been observed in terms of ADRs. The effective cost-saving of the first 2 years is greater than EUR 800,000 and it is estimated to increase over time.https://www.mdpi.com/1999-4923/13/5/684breast cancertrastuzumabbiosimilarsHER2 |
| spellingShingle | Michela Piezzo Roberta D’Aniello Ilaria Avallone Bruno Barba Daniela Cianniello Stefania Cocco Antonio D’Avino Germira Di Gioia Vincenzo Di Lauro Giuseppina Fusco Raffaele Piscitelli Claudia von Arx Michelino De Laurentiis Piera Maiolino Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center Pharmaceutics breast cancer trastuzumab biosimilars HER2 |
| title | Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center |
| title_full | Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center |
| title_fullStr | Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center |
| title_full_unstemmed | Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center |
| title_short | Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center |
| title_sort | uptake of trastuzumab biosimilars for the treatment of her2 positive breast cancer a real world experience from a cancer center |
| topic | breast cancer trastuzumab biosimilars HER2 |
| url | https://www.mdpi.com/1999-4923/13/5/684 |
| work_keys_str_mv | AT michelapiezzo uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT robertadaniello uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT ilariaavallone uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT brunobarba uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT danielacianniello uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT stefaniacocco uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT antoniodavino uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT germiradigioia uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT vincenzodilauro uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT giuseppinafusco uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT raffaelepiscitelli uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT claudiavonarx uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT michelinodelaurentiis uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter AT pieramaiolino uptakeoftrastuzumabbiosimilarsforthetreatmentofher2positivebreastcancerarealworldexperiencefromacancercenter |